-
SCALING RARE DISEASE INSIGHTS THROUGH AI-DRIVEN PHENOTYPE SEARCH ON FEDERATED NETWORKS
Aug 20, 2026, 13:29 PM -
EXPLORING STATISTICAL UNCERTAINTY OF HEALTH INTERVENTION EFFECTS IN DISCRETE CHOICE EXPERIMENTS: A FLU VACCINE CASE STUDY
Aug 20, 2026, 13:29 PM -
JOINT ESTIMATION OF MULTI-STATE TRANSITION PROBABILITIES USING KAPLAN-MEIER SURVIVAL CURVES
Aug 20, 2026, 13:29 PM -
CAN GENERATIVE AI RELIABLY IDENTIFY PAYER DECISIONS AND REPLACE MANUAL HTA REVIEW? A COMPARISON OF AI AND HUMAN EXTRACTION OF A FRENCH HTA REPORT
Aug 20, 2026, 13:29 PM -
DECISION RULES FOR MULTI-TREATMENT RECOMMENDATIONS BASED ON NET MONETARY BENEFIT, FOR RISK-NEUTRAL AND RISK-AVERSE DECISION-MAKERS
Aug 20, 2026, 13:29 PM -
VALIDATION OF A GENERAL-PURPOSE AI AGENT (CLAUDE) FOR KAPLAN-MEIER CURVE DIGITIZATION AND PARAMETRIC SURVIVAL EXTRAPOLATION
Aug 20, 2026, 13:29 PM -
WHEN UTILITY DATA ARE SCARCE: METHODS AND ACCEPTABILITY IN NICE RARE DISEASE APPRAISALS
Aug 20, 2026, 13:28 PM -
STATISTICAL LESSONS FROM EARLY EU JOINT CLINICAL ASSESSMENTS AND IMPLICATIONS FOR RARE-DISEASE HTA ACROSS EU-25: THE ROLE OF EARLY AUTOMATION IN IDENTIFYING EVIDENCE GAPS
Aug 20, 2026, 13:28 PM -
RACING AGAINST RARITY: CAN EVIDENCE GATHERED BETWEEN ENTRY AND EXIT OF CONDITIONAL ACCESS AGREEMENTS RESOLVE UNCERTAINTY IN RARE DISEASES?
Aug 20, 2026, 13:28 PM -
EU JOINT CLINICAL ASSESSMENT OF TOVORAFENIB: METHODOLOGICAL LEARNINGS FOR FUTURE ORPHAN DOSSIERS
Aug 20, 2026, 13:28 PM -
THE IMPACT OF GERMANY'S 2008 NATIONWIDE SKIN CANCER SCREENING PROGRAM ON AGE-STANDARDIZED MELANOMA MORTALITY: AN UPDATE USING SYNTHETIC CONTROL METHODS
Aug 11, 2026, 17:16 PM -
EFFICACY AND SAFETY OF PALOPEGTERIPARATIDE IN CHRONIC HYPOPARATHYROIDISM - A SYSTEMATIC LITERATURE REVIEW
Aug 11, 2026, 17:16 PM -
HEALTHCARE RESOURCE UTILIZATION (HCRU) AND ASSOCIATED COSTS IN PATIENTS WITH STAGE III MERKEL CELL CARCINOMA (MCC) TREATED WITH FIRST-LINE (1L) AVELUMAB IN A REAL-WORLD SETTING: RESULTS FROM THE MCC-TRIM REGISTRY
Aug 11, 2026, 17:16 PM -
WE-ACCESS-CLL SURVEY - REIMBURSEMENT AND ACCESS TO NOVEL FIRST-LINE TREATMENTS FOR CHRONIC LYMPHOCYTIC LEUKEMIA IN POLAND AND WESTERN EUROPE
Aug 11, 2026, 17:16 PM -
ESTIMATING THE RETURN ON PATIENT ENGAGEMENT IN CLINICAL TRIALS: EVIDENCE FROM A RISK-ADJUSTED NET PRESENT VALUE MODEL FOR A SOLID TUMOR ONCOLOGY PRODUCT
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF FIRST-LINE NIVOLUMAB-BASED THERAPY FOR HER2-NEGATIVE ADVANCED GASTRIC CANCER, GASTROESOPHAGEAL JUNCTION CANCER, AND ESOPHAGEAL ADENOCARCINOMA IN JAPAN
Aug 11, 2026, 17:16 PM -
REIMBURSEMENT AND CAPACITY IMPLICATIONS OF TRANSITIONING PATIENTS TO HOME-BASED SCIG IN SID AND CIDP: A PRACTICE-LEVEL ECONOMIC MODEL IN GERMANY
Aug 11, 2026, 17:16 PM -
ECONOMIC AND ORGANIZATIONAL ANALYSIS OF ES-SCLC IMMUNOTHERAPIES: A FRAMEWORK FOR APPROPRIATE SUSTAINABILITY IN THE ITALIAN NHS
Aug 11, 2026, 17:16 PM -
ENRICHING REAL-WORLD TREATMENT-PATTERN ANALYSIS IN OVERACTIVE BLADDER BY LINKING NORSTELLALINQ CLAIMS WITH NORSTELLALINQ ELECTRONIC HEALTH RECORD NOTES USING MANUAL CLINICAL REVIEW
Aug 11, 2026, 17:16 PM -
REAL-WORLD EVIDENCE (RWE) READINESS FOR EU JOINT CLINICAL ASSESSMENT: GAP ANALYSIS BETWEEN CURRENT RWE STUDIES AND EU HTA EXPECTATIONS
Aug 11, 2026, 17:16 PM
